What GLP1 Does Pfizer Make? The Straight Answer (2026)

Published: June 18, 2026 · Last reviewed: June 18, 2026

By The RX Index Editorial Team · Last verified: June 2026

So you keep seeing Pfizer's name next to weight-loss headlines, and you want a straight answer to one question: what GLP1 does Pfizer make? Here it is. As of June 2026, Pfizer does not sell a single GLP-1 you can get with a prescription in the United States. Not one. The drug most people mean is berobenatide, an investigational GLP-1 shot that's still in clinical trials. Pfizer also sells a GLP-1 called Xianweiying — but only in China, and it didn't even invent it.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

What GLP-1 does Pfizer make right now?

Right now, Pfizer's main GLP-1 is berobenatide — an investigational GLP-1 receptor agonist that is not approved or for sale anywhere yet. It also has exclusive rights to sell ecnoglutide (brand name Xianweiying) in Mainland China, where it's approved, but Pfizer is the seller there, not the inventor. In the United States, Pfizer has no GLP-1 you can get.

Here's why this question trips people up: "Pfizer's GLP-1" can mean five different things, and most articles only cover one. A drug can be something Pfizer invented, bought, licensed, sells in one country, or already gave up on. None of those is the same as "a Pfizer pill or shot your doctor can prescribe in the US."

The answer by where you live

The answer by the name you saw in a headline

The takeaway in one line: Pfizer is spending billions to build a GLP-1 business, but every US-relevant drug it has is either still in trials or already discontinued.

Is any Pfizer GLP-1 FDA-approved or available in the US?

No. As of June 2026, Pfizer has no FDA-approved GLP-1 for weight loss or diabetes that a US patient can be prescribed. Berobenatide is investigational (still being tested). Danuglipron and lotiglipron were discontinued. And Xianweiying is approved in China only — not by the FDA.

A few definitions worth having. "FDA-approved" means the U.S. Food and Drug Administration has approved the drug for a specific use, so a doctor can prescribe it and a pharmacy can fill it. "Investigational" means the drug is still in clinical trials and is not available. "Discontinued" means the company stopped development — the drug doesn't exist for patients.

Before you act on any Pfizer GLP-1 headline, check these five things:

1. Is the drug FDA-approved, or just investigational?
2. Is it approved for weight loss, type 2 diabetes, or something else?
3. Is it actually for sale in the US — or only in another country like China?
4. Is Pfizer the maker, the buyer, the license-holder, or just the seller in one market?
5. Is the article current, or is it old danuglipron news dressed up as new?

What is berobenatide, Pfizer's lead GLP-1?

Berobenatide is Pfizer's most advanced GLP-1: an investigational, ultra-long-acting GLP-1 receptor agonist now in Phase 3 trials for weight management. Pfizer is studying it in both weekly and monthly dosing — the monthly-maintenance version is what people mean when they call it "Pfizer's monthly GLP-1." Pfizer got it by buying the biotech Metsera in November 2025 for up to about $10 billion. Its older names are PF-08653944, PF'3944, and MET-097i — all the same drug.

Why the buzz? Today's blockbuster GLP-1s (like Wegovy and Zepbound) are weekly shots. Berobenatide is being built so you'd ramp up with weekly doses, then switch to a once-a-month maintenance shot — fewer injections, easier to stick with. Pfizer calls it a potential "first-in-class monthly GLP-1." In its Phase 2b VESPER-1 study, the highest weekly dose led to almost 16% average weight loss at 32 weeks, with no plateau yet, and the monthly study (VESPER-3) hit its main goal too.

So when can you get it? Not soon. Pfizer hasn't announced an FDA approval date. After the ADA meeting, analysts expected the first Phase 3 results in the second half of 2027 and monthly-regimen data in 2028, and Pfizer's CEO has pointed to a 2028 launch window — all of which depends on the trials succeeding and the FDA signing off.

If you were hoping berobenatide was your ticket and that timeline doesn't work for you, that's the whole reason this next step exists. Want to see which GLP-1 treatment paths you can actually start now?

What happened to Pfizer's weight-loss pill, danuglipron?

Pfizer discontinued danuglipron, its oral GLP-1 pill, on April 14, 2025, after a trial participant had a case of possible drug-related liver injury that went away once the drug was stopped. That's why older "Pfizer's weight-loss pill" articles are misleading — the pill they're hyping no longer exists.

The frustrating part for Pfizer is that danuglipron actually worked. In testing, it produced real, statistically significant weight loss. But the twice-a-day version had a rough side-effect problem — more than half of people dropped out, mostly from nausea and other gut issues. Pfizer pivoted to a once-daily version, which looked better on paper. Then a single trial volunteer showed signs of liver injury, and combined with feedback from regulators, Pfizer pulled the plug. It wasn't Pfizer's first GLP-1 pill to fall, either — an earlier one, lotiglipron, was dropped back in 2023 over similar liver-enzyme concerns.

Does Pfizer make a GLP-1 pill now?

Pfizer does not have a GLP-1 pill you can get. Its active oral GLP-1 pipeline includes two early-stage candidates — both in Phase 1 — and neither is approved or available as a prescription. Its older pill, danuglipron, was discontinued.

In December 2025, Pfizer licensed worldwide rights to YP05002, an oral small-molecule GLP-1, from YaoPharma (a Chinese drugmaker under Fosun Pharma). Pfizer paid $150 million up front, with up to about $1.935 billion more if the drug hits its goals. Separately, Pfizer's Metsera deal brought in its own oral GLP-1 candidate, also in Phase 1. So Pfizer has two oral GLP-1s in early development — which makes sense, because an oral pill is exactly the thing Pfizer kept failing to make on its own.

Here's the reality check: Phase 1 is the earliest stage of human testing, and most drugs in Phase 1 never reach pharmacy shelves. Bottom line: a Pfizer GLP-1 pill is a maybe-someday, not a now. Don't plan your health around it.

What is Xianweiying (ecnoglutide), and is it really "Pfizer's GLP-1"?

Xianweiying — generic name ecnoglutide — is a GLP-1 injection approved in China for long-term weight management. Pfizer has the exclusive rights to sell it in Mainland China, but a company called Sciwind Biosciences invented and makes it. It is not available in the US, and it is not FDA-approved.

This is the one place Pfizer can genuinely say it "has" a GLP-1 on the market — but the wording matters. In February 2026, Pfizer signed a deal worth up to $495 million for exclusive rights to commercialize ecnoglutide in Mainland China. Under that deal, Sciwind stays the official maker — handling research, manufacturing, and supply — while Pfizer sells it. China's regulator (the NMPA) approved it for long-term weight management on March 6, 2026, and it launched on April 27, 2026. It's a once-weekly shot, and in a 48-week trial the highest dose produced about 15.4% average weight loss from baseline.

So is it "Pfizer's GLP-1"? Sort of. Pfizer sells it; Sciwind built it; and either way, it stops at China's border. To be crystal clear: Pfizer does not make an FDA-approved GLP-1, Pfizer's GLP-1 is not available in the US, and Xianweiying is not "Pfizer's Ozempic" — it's a China-only product Pfizer distributes.

Does Pfizer make Ozempic, Wegovy, Zepbound, or Mounjaro?

No. Pfizer makes none of the famous GLP-1 brands. Ozempic, Wegovy, and Rybelsus are made by Novo Nordisk. Zepbound and Mounjaro are made by Eli Lilly. Pfizer is a different company that's still trying to get its first GLP-1 to market.

Getting this right matters for one practical reason: if a headline makes it sound like Pfizer just launched a GLP-1, you might waste time waiting — or worse, buy from a sketchy "Pfizer GLP-1" seller online. There is no legitimate US Pfizer GLP-1 to buy. Anyone claiming to sell you one is a red flag.

Can you join a Pfizer GLP-1 clinical trial?

Possibly — but being in a clinical trial is not the same as getting a prescription, and you can't buy the drug outside a legitimate study. Pfizer is running Phase 3 trials of berobenatide, such as the once-monthly VESPER-6 study (trial ID NCT07595549), which has been recruiting people with overweight or obesity. Eligibility, locations, and whether a trial is still enrolling change often.

If you want to explore this, the place to look is ClinicalTrials.gov (search "berobenatide" or "PF-08653944") or Pfizer's own clinical-trials site. A few honest notes before you do: trials have strict eligibility rules, you might receive a placebo instead of the drug, and joining a study is a medical decision you should talk through with your own clinician. It's a real option for some people — just not a shortcut to a Pfizer prescription that doesn't exist yet.

Should you wait for Pfizer — or start an available GLP-1 now?

For most people who want to start treatment soon, waiting on Pfizer doesn't make sense — its US drugs are either in trials or discontinued. The better question is which available GLP-1 fits your situation. Effective, FDA-approved GLP-1s already exist, just not from Pfizer.

If your goal is weight loss or blood-sugar control today, the medicines you can actually get come from Novo Nordisk and Eli Lilly. That includes semaglutide (Ozempic, Wegovy, Rybelsus, and an oral version of Wegovy the FDA approved in December 2025) and tirzepatide (Mounjaro and Zepbound). There's even a newer FDA-approved GLP-1 pill, orforglipron (Foundayo), which Eli Lilly launched in April 2026 — proof that the oral GLP-1 Pfizer keeps chasing has already arrived from a competitor.

These are prescription medicines with real risks and eligibility limits, and a licensed clinician decides whether any GLP-1 is right for your medical history. Which one fits honestly depends on you — your state, your insurance and formulary, whether you want a pill or a shot, and your budget. A general article can't sort that out. (One more thing worth knowing: compounded GLP-1 medications are not FDA-approved and are a different thing from the brand-name drugs above — don't treat them as the same.)

If you want to go deeper, our guides on FDA-approved brand-name GLP-1 providers, GLP-1 cost without insurance, and the best GLP-1 options for diabetes break down the next steps.

Here's your fastest move. Instead of guessing, get a personalized match: Find My GLP-1 Path lines up available treatment paths by your state, insurance, medication type, and budget — with source-verified pricing — so you can see real options in about a minute.

How we verified this

We built this page from Pfizer's own press releases, Pfizer's SEC filings, Sciwind's statements, and credible news coverage — not from rumor or recycled blog posts. We used reader forums only to understand how people phrase the question, never as evidence for any medical or regulatory claim.

What we actually verified — June 2026:

• Pfizer has no FDA-approved GLP-1 available to US patients. (All programs are investigational or discontinued.)
• Berobenatide (PF-08653944 / PF'3944, formerly MET-097i) is Pfizer's lead GLP-1, now in Phase 3, with detailed Phase 2b data shown at the ADA meeting in June 2026.
• Danuglipron was discontinued April 14, 2025; lotiglipron was discontinued in 2023.
• Pfizer completed its Metsera acquisition (~$10 billion) on November 13, 2025.
• YP05002, an oral GLP-1 licensed from YaoPharma in December 2025, is in Phase 1, alongside a separate Phase 1 oral GLP-1 from Metsera.
• Ecnoglutide (Xianweiying) was approved in China for weight management on March 6, 2026 and launched April 27, 2026; Pfizer commercializes it in Mainland China while Sciwind remains the maker.

We re-check this page often, because drug pipelines move fast. If a trial reads out, a drug gets approved, or a status changes, we update the table and the date above.

Pfizer's GLP-1 timeline: 2023 to 2026

Pfizer's GLP-1 story flipped fast — from two failed pills to a $10 billion buyout to a China launch — all in about three years. If you only saw one headline, you only saw one frame of the movie. Here's the whole reel.

Frequently asked questions

How this page was made: The RX Index Editorial Team built this guide by checking Pfizer's press releases, SEC filings (Forms 8-K and 10-Q), Sciwind Biosciences' announcements, and credible news coverage for approval and launch details. We don't use anonymous forum posts as evidence for medical or regulatory facts. Last verified: June 2026.

Sources

• Pfizer — "Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide" (June 2026, ADA data)
• Pfizer — "Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust... (VESPER-3)" Feb 3, 2026
• BioPharma Dive — "ADA '26: Lilly's dominance, Pfizer's 'foundational' drug..." (June 2026)
• Pfizer — "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron," April 14, 2025 (discontinuation)
• Pfizer — "Pfizer Provides Update on GLP-1-RA Clinical Development Program," June 26, 2023 (lotiglipron discontinuation)
• Pfizer — "Pfizer Completes Acquisition of Metsera," Nov 13, 2025
• Pfizer — "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma," Dec 9, 2025 (YP05002, Phase 1)
• Sciwind Biosciences — Strategic commercialization collaboration with Pfizer for ecnoglutide, Feb 24, 2026
• Reuters — "Pfizer GLP-1 weight loss drug available for pre-order in China," April 22, 2026 (JD.com listing: 1.2 mL pen, 489 yuan / ~$72, shipping April 27)
• AJMC / Eli Lilly — orforglipron (Foundayo) FDA approval, April 1, 2026; Novo Nordisk — oral semaglutide (Wegovy pill) FDA approval, Dec 2025